Be a Smart Investor
Thursday, January 3, 2019
Bristol-Myers Squibb's $74 billion acquisition of Celgene would combine two troubled companies
Bristol Myers-Squibb is acquiring Celgene in a cash and stock deal valued at $74 billion. Some view the deal as an act of survival.
from Deals and IPOs https://cnb.cx/2F61TbC
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment